Tags: US | FDA | Cancer | Drug

FDA Approves Dendreon's Cancer Drug Provenge

Friday, 30 Apr 2010 08:15 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

The Food and Drug Administration has approved a first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease, offering an important alternative to decades-old approaches.

Dendreon Corp.'s Provenge vaccine trains the immune system to fight tumors. It's called a "vaccine" even though it treats disease rather than prevents it.

Doctors have been trying to develop such a therapy for decades, and Provenge is the first to successfully prolong patient lives.

The drug is intended to treat cancer that has spread elsewhere in the body and is not responding to hormone therapy. Provenge is made by taking immune cells from a patient's blood and exposing them to a protein found in most prostate cancers. That encourages the cells to attack the cancer.

Provenge is given intravenously, with a total of three doses given approximately once every two weeks. The agency said 192,000 new cases of prostate cancer were diagnosed in 2009, and 27,000 men died of the disease. Prostate cancer most often affects older men.

Side effects of Provenge include chills, fatigue, fever, back pain, nausea, joint ache, and headache, the FDA said.

Shares of Seattle-based Dendreon jumped 19 percent to new highs ahead of the news, rising to an all-time high of $47.32. Trading of the stock was halted at 12:34 p.m. Eastern, 35 minutes before the FDA announced its decision. At the time, Dendreon shares were up $5.88, or 14.8 percent, at $45.50.

The company does not have any products on the market. Prostate cancer is usually treated with surgery, radiation, or medicine that blocks testosterone.

The only drug approved to treat advanced prostate cancer is Sanofi-Aventis's Taxotere, a chemotherapy agent. Last year, Dendreon said a clinical trial showed patients treated with Provenge lived for about a month longer than men treated with Taxotere.

Sanofi-Aventis is also working on a new drug for advanced prostate cancer called Jevtana. That drug is related to Taxotere, but may be better at improving survival.

© Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Ebola Gets Hollywood Treatment

Monday, 20 Oct 2014 10:23 AM

As anxiety over Ebola intensifies, some big names in Hollywood are looking to profit from the public angst. . . .

Apocalyptic Themes in Films Reflect Tumultuous Times

Monday, 13 Oct 2014 10:05 AM

The end of the world is a theme that has been finding its way into numerous modes of entertainment and a wide variety of . . .

Piers Morgan Vows Anti-gun Documentary

Monday, 06 Oct 2014 08:43 AM

There is no love lost between Morgan and the countless numbers of Americans who have a deep respect for the Constitution . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved